CryoLife BioGlue Vascular Approval To Double Sales Of The Adhesive In 2002
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of CryoLife's BioGlue for vascular repair procedures, announced Dec. 4, is expected to roughly double sales of the surgical adhesive to $22-24 mil. in 2002, the firm says
You may also be interested in...
CryoLife BioGlue Gel Formulation Among 11 Related Applications In Pipeline
CryoLife is opting not to pursue a general surgery indication in the U.S. for its BioGlue surgical adhesive
CryoLife BioGlue Gel Formulation Among 11 Related Applications In Pipeline
CryoLife is opting not to pursue a general surgery indication in the U.S. for its BioGlue surgical adhesive
CryoLife BioGlue PMA Clears FDA Panel With Minimal Conditions
One member of FDA's Circulatory System Devices Panel suggested that the agency look into the number of transfusions performed when surgeons use CryoLife's BioGlue surgical adhesive, but stopped short of recommending it as a condition of approval during the panel's Sept. 11 review of the product.